BioWorld

Nov. 3, 2006

XOMA, Takeda In Antibody Deal With $100M Potential

XOMA Ltd. could receive more than $100 million in a collaboration with Takeda Pharmaceutical Co. Ltd. to discover and develop monoclonal antibody therapeutics. (BioWorld Today) Read More

Exelixis' Stock Falls After XL999 Phase II Suspension

TopoTarget, LEO Deal Gives CuraGen Payoff For License

Gamida Cell Earns SPA To Begin Phase III For StemEx

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.